A meta-analysis (43) including 33 studies revealed that axillary lymph node pCR rates by breast cancer subtypes in patients with cN+ were 60%, 45%, 48%, and 18% for HR-/HER2+, HR+/HER2+, HR-/HER2-, and HR+/HER2-, respectively. This evidence concerns the gene ERBB2 and breast cancer.